NASDAQ$CGEM
Cullinan Oncology Inc · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Cullinan Oncology reported third quarter 2023 financial results and provided a corporate update.
Cullinan Oncology reported a net loss of $39.2 million for the third quarter of 2023. As of September 30, 2023, the company's cash and investment position was $482 million, expected to provide runway into the second half of 2026.
- Cash and investment position of $482 million as of September 30, 2023, expected to provide runway into the second half of 2026.
- Enrollment continues in the pivotal Phase 2b portion of the zipalertinib REZILIENT1 study, with completion expected by the end of 2024.
- Initial CLN-619 clinical biomarker data support mechanism of action and demonstrate monotherapy clinical activity.
- Cullinan expects to report initial data from the combination dose escalation module as well as an update on the monotherapy dose escalation module at a medical conference in the second quarter of 2024.
Headline financials
Revenue & EPS history
Cullinan Oncology · Revenue · Quarterly
$200K
Forward guidance
Cullinan Oncology anticipates several milestones in the near term.
Tailwinds
- Initial data from the CLN-619 combination therapy module in Q2 2024.
- Additional CLN-619 monotherapy data from the Phase 1 dose escalation study in Q2 2024.
- Initial data from CLN-619 disease-specific expansion cohorts in H1 2025.
- Completion of enrollment in the pivotal Phase 2b portion of the zipalertinib REZILIENT1 study by the end of 2024.
- Data presentation for CLN-049 and CLN-418 in the second half of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
+0.5%
Avg return
Earnings day
-0.2%
Avg return
5 days after
-2.1%
Avg return
30 days after
55%
11 / 20 earnings
Positive
+13.5%
Q1 2022
Best reaction
-10.8%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -2.6% | +7.7% | -10.0% | |
| Q3 2025 | +0.8% | +6.7% | +44.9% | |
| Q2 2025 | -10.8% | -7.7% | -11.3% | |
| Q1 2025 | +2.3% | +1.3% | +5.8% | |
| Q4 2024 | +1.9% | -3.8% | -5.1% | |
| Q3 2024 | -2.8% | -2.8% | -20.8% | |
| Q1 2024 | -9.7% | -9.1% | -28.4% | |
| Q4 2023 | -6.2% | -8.7% | -1.8% | |
| Q3 2023 | -2.7% | -11.1% | -17.7% | |
| Q2 2023 | +4.3% | -1.4% | -0.6% | |
| Q1 2023 | +1.2% | -5.3% | +36.0% | |
| Q4 2022 | -1.5% | +3.3% | -9.1% | |
| Q3 2022 | +3.8% | +1.0% | -3.0% | |
| Q2 2022 | -5.6% | +0.8% | -3.5% | |
| Q1 2022 | +13.5% | +6.8% | +12.1% | |
| Q4 2021 | +8.8% | +3.0% | -8.6% | |
| Q3 2021 | -4.5% | -10.1% | -28.8% | |
| Q2 2021 | +7.8% | +3.8% | +8.0% | |
| Q1 2021 | +2.2% | +12.4% | +13.1% | |
| Q4 2020 | +9.5% | +8.4% | -13.9% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro